Literature DB >> 28213435

Genetics of Synucleinopathies.

Robert L Nussbaum1.   

Abstract

Parkinson's disease (PD), diffuse Lewy body disease (DLBD), and multiple system atrophy (MSA) constitute the three major neurodegenerative disorders referred to as synucleinopathies because both genetic and pathological results implicate the α-synuclein protein in their pathogenesis. PD and DLBD are recognized as closely related diseases with substantial clinical and pathological overlap. MSA, on the other hand, has a distinctive clinical presentation and neuropathological profile. In this review, we will summarize the evidence linking α-synuclein to these three disorders. Hundreds of patients with point or copy number mutations in the gene encoding α-synuclein, SNCA, have been reported in the literature in association with hereditary, autosomal dominant forms of PD, DLBD, or neurodegenerative disease with parkinsonism. The copy number mutations show a dosage effect with age at onset and severity correlating with the number of extra copies of SNCA a patient carries. Common variation in and around the SNCA gene has also been found by genome-wide association studies to be associated with increased risk for apparently sporadic PD, with some evidence that these variants exert their effect through modest increases in α-synuclein expression. Complementing the genetic evidence linking α-synuclein to PD and DLBD is the pathological finding that α-synuclein is a major constituent of Lewy bodies and Lewy neurites in the brains of patients with the common sporadic form of PD. On the other hand, there is little genetic evidence linking SNCA to MSA despite strong neuropathological evidence of α-synuclein aggregation in oligodendroglial cells in MSA patients. Evidence is now emerging that α-synuclein aggregates can have different protein conformations, referred to as strains, similar to what has been shown in prion disease. The different phenotypes in hereditary PD/DLBD versus MSA are likely, therefore, to be the result not only of how specific mutations affect protein expression and turnover, but also a more complex interaction between intrinsic and extrinsic factors governing aggregation and strain formation.
Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28213435      PMCID: PMC5983162          DOI: 10.1101/cshperspect.a024109

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  52 in total

1.  Parkinsonism: onset, progression, and mortality. 1967.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  2001-11       Impact factor: 9.910

Review 2.  Autosomal dominant Parkinson's disease caused by SNCA duplications.

Authors:  Takuya Konno; Owen A Ross; Andreas Puschmann; Dennis W Dickson; Zbigniew K Wszolek
Journal:  Parkinsonism Relat Disord       Date:  2015-09-03       Impact factor: 4.891

Review 3.  Pathology and biology of the Lewy body.

Authors:  M S Pollanen; D W Dickson; C Bergeron
Journal:  J Neuropathol Exp Neurol       Date:  1993-05       Impact factor: 3.685

4.  Eight prion strains have PrP(Sc) molecules with different conformations.

Authors:  J Safar; H Wille; V Itri; D Groth; H Serban; M Torchia; F E Cohen; S B Prusiner
Journal:  Nat Med       Date:  1998-10       Impact factor: 53.440

5.  Mapping of a gene for Parkinson's disease to chromosome 4q21-q23.

Authors:  M H Polymeropoulos; J J Higgins; L I Golbe; W G Johnson; S E Ide; G Di Iorio; G Sanges; E S Stenroos; L T Pho; A A Schaffer; A M Lazzarini; R L Nussbaum; R C Duvoisin
Journal:  Science       Date:  1996-11-15       Impact factor: 47.728

6.  Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions.

Authors:  Masato Hasegawa; Hideo Fujiwara; Takashi Nonaka; Koichi Wakabayashi; Hitoshi Takahashi; Virginia M-Y Lee; John Q Trojanowski; David Mann; Takeshi Iwatsubo
Journal:  J Biol Chem       Date:  2002-10-10       Impact factor: 5.157

7.  alpha-Synuclein gene haplotypes are associated with Parkinson's disease.

Authors:  M Farrer; D M Maraganore; P Lockhart; A Singleton; T G Lesnick; M de Andrade; A West; R de Silva; J Hardy; D Hernandez
Journal:  Hum Mol Genet       Date:  2001-08-15       Impact factor: 6.150

8.  Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain.

Authors:  Kenneth D Cronin; Dongliang Ge; Paul Manninger; Colton Linnertz; Anna Rossoshek; Bonnie M Orrison; David J Bernard; Omar M A El-Agnaf; Michael G Schlossmacher; Robert L Nussbaum; Ornit Chiba-Falek
Journal:  Hum Mol Genet       Date:  2009-06-04       Impact factor: 6.150

Review 9.  A53T in a parkinsonian family: a clinical update of the SNCA phenotypes.

Authors:  Nicola Tambasco; Pasquale Nigro; Michele Romoli; Paolo Prontera; Simone Simoni; Paolo Calabresi
Journal:  J Neural Transm (Vienna)       Date:  2016-06-01       Impact factor: 3.575

10.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.

Authors:  K Uéda; H Fukushima; E Masliah; Y Xia; A Iwai; M Yoshimoto; D A Otero; J Kondo; Y Ihara; T Saitoh
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

View more
  27 in total

1.  Molecular mechanism of olesoxime-mediated neuroprotection through targeting α-synuclein interaction with mitochondrial VDAC.

Authors:  Amandine Rovini; Philip A Gurnev; Alexandra Beilina; María Queralt-Martín; William Rosencrans; Mark R Cookson; Sergey M Bezrukov; Tatiana K Rostovtseva
Journal:  Cell Mol Life Sci       Date:  2019-11-23       Impact factor: 9.261

Review 2.  Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Authors:  Michael G Erkkinen; Mee-Ohk Kim; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

Review 3.  Neurodegenerative Disease Transmission and Transgenesis in Mice.

Authors:  Brittany N Dugger; Daniel P Perl; George A Carlson
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-11-01       Impact factor: 10.005

Review 4.  Dynamic behaviors of α-synuclein and tau in the cellular context: New mechanistic insights and therapeutic opportunities in neurodegeneration.

Authors:  Fred Yeboah; Tae-Eun Kim; Anke Bill; Ulf Dettmer
Journal:  Neurobiol Dis       Date:  2019-07-24       Impact factor: 5.996

Review 5.  Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Authors:  J A Obeso; M Stamelou; C G Goetz; W Poewe; A E Lang; D Weintraub; D Burn; G M Halliday; E Bezard; S Przedborski; S Lehericy; D J Brooks; J C Rothwell; M Hallett; M R DeLong; C Marras; C M Tanner; G W Ross; J W Langston; C Klein; V Bonifati; J Jankovic; A M Lozano; G Deuschl; H Bergman; E Tolosa; M Rodriguez-Violante; S Fahn; R B Postuma; D Berg; K Marek; D G Standaert; D J Surmeier; C W Olanow; J H Kordower; P Calabresi; A H V Schapira; A J Stoessl
Journal:  Mov Disord       Date:  2017-09       Impact factor: 10.338

Review 6.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

Review 7.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

8.  Electron Microscopic Analysis of α-Synuclein Fibrils.

Authors:  Airi Tarutani; Masato Hasegawa
Journal:  Methods Mol Biol       Date:  2021

9.  Sabotage by the brain's supporting cells helps fuel neurodegeneration.

Authors:  Lary C Walker
Journal:  Nature       Date:  2018-05       Impact factor: 49.962

10.  Pulsed Hydrogen-Deuterium Exchange Illuminates the Aggregation Kinetics of α-Synuclein, the Causative Agent for Parkinson's Disease.

Authors:  Eva Illes-Toth; Don L Rempel; Michael L Gross
Journal:  ACS Chem Neurosci       Date:  2018-04-11       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.